Shiga toxin
From Proteopedia
IntroductionShiga Toxins are a family of AB5 toxins (Stx1 and Stx2) which cause dysentery, hemolytic-uremic syndrome, and potentially renal failure in humans. They are primarily secreted by Shiga toxin-encoding Escherichia coli (STEC), notably by the 0157:H7 strain[1] and shigella dysentarie. STECs are one of the major foodborne pathogens, affecting both developed and third-world countries. The stx gene is not endogenous to these strains, but is introduced through horizontal gene transfer from environmental prophages of the lambdoid bacteriophage family and incorporated into the E. Coli genome.[1] Shiga Toxins are closely related to ricin, which is structurally and mechanistically similar. Shiga toxin acts to inhibit protein synthesis in eukaryotic cells and is the main virulence factor of STEC. For toxins in Proteopedia see Toxins. Human Interaction0157:H7 STECs are spread to humans through a fecal-oral mechanism, primarily from ingestion of food contaminated with fecal material. Cattle, goats, and sheep are the primary reservoir of STECs and their close proximity to food sources as well as the use of animal feces for fertilizer makes them the main route of contamination.[2] These animals can house STEC's without effect due to a lack of Stx surface receptors.[3] Inadequate sanitation and contamination of meat during slaughter can both lead to STEC contaminated food at the market. Once ingested the STEC can survive the high acid environment of the stomach and progress to the gut where they attach firmly to gut mucosa via the intimin adhesin protein.[4] Secreted Stx then either attacks gut epithelia or passes into the bloodstream where it can damage kidney and brain tissue. TreatmentsTreatment with antibiotics is contraindicated as antibiotic treatment has been demonstrated to increase Stx production up to one hundred fold.[2] This results from the link between Stx production (and phage induction) to the SOS response pathway.[2] In the event of renal failure kidney dialysis may be employed. A number of potential treatments are under development including B subunit inhibitors, polysaccharides that promote macrophage uptake of Stx, blocking of the Gb3 membrane receptor, and inhibition of retrograde transport.[5] StructureShiga Toxin consists consists of an AB5 hexamer.[6] The 5 subunit B pentamer interacts with the A subunit via a C-terminal helix of hydrophobic subunits packed antiparallel to 5 B helixes and 4 antiparallel beta sheets.[6]. The glycosidase active site is located on the A subunit, but is blocked by the B subunit until the disulphide bond between cys242 and cys261 is cleaved releasing an active A subunit into the target cell.[6] FunctionShiga Toxin acts as an N-glycosidase, removing an adenine from the 28S ribosomal rRNA of a target cell which leads to inhibition of protein elongation and ultimately cellular apoptosis.[7] The B subunit is necessary for binding to globo series glycolipid globotriaosylceramide (Gb3), a eukaryotic membrane receptor, where it is then endocytosed and proteolytically cleaved into an active A subunit and a B subunit.[8] The B subunit is not active in the depurination of of 28S rRNA, but is essential for GB3 binding and therefore essential for toxicity. Once in the cytosol the A subunit is free to interact with and inactivate 28S rRNA. On the A subunit Tyr77, Tyr114, Glu167, Arg170, and Trp203 are all essential in glycosidic activity.[7] This mechanism (B subunit binding to globotriaosylceramide and A subunit depurinating 28S rRNA) is conserved amongst the Stx family as well as the ricin toxin. 3D structures of shiga toxin
|
|
References
- ↑ 1.0 1.1 Wagner PL, Livny J, Neely MN, Acheson DW, Friedman DI, Waldor MK. Bacteriophage control of Shiga toxin 1 production and release by Escherichia coli. Mol Microbiol. 2002 May;44(4):957-70. PMID:12010491
- ↑ 2.0 2.1 2.2 Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages--genomes in motion. Int J Med Microbiol. 2004 Sep;294(2-3):115-21. PMID:15493821
- ↑ Asakura H, Makino S, Kobori H, Watarai M, Shirahata T, Ikeda T, Takeshi K. Phylogenetic diversity and similarity of active sites of Shiga toxin (stx) in Shiga toxin-producing Escherichia coli (STEC) isolates from humans and animals. Epidemiol Infect. 2001 Aug;127(1):27-36. PMID:11561972
- ↑ Russell JB, Jarvis GN. Practical mechanisms for interrupting the oral-fecal lifecycle of Escherichia coli. J Mol Microbiol Biotechnol. 2001 Apr;3(2):265-72. PMID:11321582
- ↑ Nishikawa K. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli. Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):239-47. Epub 2011 Jun 5. PMID:21644029 doi:10.1007/s00005-011-0130-5
- ↑ 6.0 6.1 6.2 Fraser ME, Chernaia MM, Kozlov YV, James MN. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol. 1994 Jan;1(1):59-64. PMID:7656009
- ↑ 7.0 7.1 Di R, Kyu E, Shete V, Saidasan H, Kahn PC, Tumer NE. Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae. Toxicon. 2011 Mar 15;57(4):525-39. Epub 2010 Dec 22. PMID:21184769 doi:10.1016/j.toxicon.2010.12.006
- ↑ Roman F, Santa A, Rimanoczky A, Toldi Z, Pataki L. [Isotope study of in vitro K(+) uptake and release of erythrocytes in juvenile diabetes with 86Rb]. Padiatr Grenzgeb. 1990;29(4):339-45. PMID:2170899